Epidemiology of the Nasal Flora at the Reference Center for Cystic Fibrosis of Queen Fabiola Children's University Hospital.

NCT03911258 | Unknown

• 1 other identifier: P2018/PNEUMO/FLONAMUC
• Study Type: interventional
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

Cystic fibrosis (CF) is the most common autosomal recessive inherited genetic disorder in North America, Australia and Europe. CF is due to cystic fibrosis transmembrane conductance regulator gene mutation (CFTR) coding for a chloride channel located at the apical membrane of epithelial cells. The most common mutation is the deletion of the amino acid phenylalanine at the codon 508 (ΔF508) affecting 70% of the patients. The CFTR channel participates in the regulation of the volume and composition of exocrine secretions. At the level of the lungs, this results in a thickening of the mucus with a dysfunction of the mucociliary clearance promoting colonization of pathogenic microorganisms. Patients with cystic fibrosis therefore have a natural susceptibility to develop acute and then chronic respiratory infections, gradually leading to irreversible respiratory tract lesions called bronchiectasis. Different germs such as Haemophilus influenzae and Staphylococcus aureus colonize the airways early in life. The progression of the disease causes furthermore a colonization by opportunistic germs such as Pseudomonas aeruginosa and Burkholderia cepacia, which are associated with higher mortality. Pulmonary exacerbation is a common complication of CF requiring administration of antibiotics. The choice of these antibiotics depends on the germs that the patient carries in his respiratory tract. The type of sampling and the conditions under which they are taken are therefore very important. Sputum and oropharyngeal smear are used in adolescents and children respectively to collect respiratory secretions in clinical routine. The recent literature describes induced sputum, obtained after a physiotherapy session and a hypertonic serum aerosol, as superior to the oropharyngeal smear alone and equivalent to bronchoalveolar lavage for the evaluation of the microbiological profile of patients who cannot expectorate. However, this technique takes time and requires the presence of a physiotherapist. Bronchoalveolar lavage is reserved for complex cases that do not respond to standard treatments. Finally, the nasal flora appears to be involved in the colonization of the lower respiratory tract. Sinuses are described as reservoirs of germs that can induce a recolonization of the lungs despite eradication of the germ (for example after a pulmonary transplantation) . To our knowledge, no study has investigated the involvement of nasal flora in the clinical course of children with CF.

Conditions

Cystic Fibrosis

Outcome Measures

Primary Outcomes (1)

• concordance between the microbiological results obtained by nasal lavage or swab and sputum in children

  To see if there is any correlation in the cultures of pathogens present in the upper and lower respiratory tracts for any combination of samples taken

  Day 1

Secondary Outcomes (5)

• Impact of upper respiratory microbial flora in the patient clinical course

  Day 60

• Safety evaluation of the of the different methods of sampling

  Day 1

• Tolerance of the different methods of sampling

  Day 1

• Tolerance of the different methods of sampling

  Day 1

• Tolerance of the different methods of sampling

  Day 60

Study Arms (1)

Nasal flora in CF patient

EXPERIMENTAL

Procedure: nasopharyngeal swab versus nasal wash

Interventions

nasopharyngeal swab versus nasal wash PROCEDURE

The type of procedure will be determine according to patient collaboration

Nasal flora in CF patient

Eligibility Criteria

• Age: Up to 20 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Cystic fibrosis patients aged 0-20y followed in Cystic fibrosis at HUDERF
• For each participant, both parents or legally acceptable representative(s) must sign an informed consent form (ICF) indicating that they understand the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study.
• Assent is also required of children capable of understanding the study (typically participants 7 years of age and older).

You may not qualify if:

• Any clinical situation that prohibit the taking of samples as defined in this protocol:
• Severe respiratory distress
• An altered state of consciousness
• A pulmonary complication contrary to the realization of respiratory physiotherapy (pneumothorax, hemoptysis).

Sponsors & Collaborators

• Queen Fabiola Children's University Hospital: lead

Study Sites (1)

Hôpital Universitaire Des Enfants Reine Fabiola

Brussels, 1020, Belgium

Location

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases

Study Officials

• Jean-Christophe Beghin, MD

  Queen Fabiola Children's University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 4, 2019
• First Posted: April 11, 2019
• Study Start: February 6, 2019
• Primary Completion: April 30, 2020
• Study Completion: April 30, 2020
• Last Updated: April 16, 2019

Record last verified: 2019-03

Locations

BE (1)